Black Diamond Therapeutics appoints Wendy L. Dixon to board; Brad Bolzon resigns

Black Diamond Therapeutics, Inc.

Brad Bolzon resigned from the Board effective April 5, 2022; not due to any disagreement with the company.
Wendy L. Dixon, Ph.D., appointed as Class III director effective April 6, 2022; deemed independent under Nasdaq rules.
Dr. Dixon brings over 40 years biopharma experience, including former CMO of Bristol Myers Squibb and board seats at Alkermes, Incyte, Arvinas.
She will receive standard non-employee director compensation and enter into an indemnification agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brad Bolzon

Director

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2022-04-05
Filed: April 7, 2022, 7:59 PM ET

On April 5, 2022, Brad Bolzon, Ph.D. notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), effective immediately.

Appointed

Wendy L. Dixon

Class III Director

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2022-04-06
Filed: April 7, 2022, 7:59 PM ET

On April 6, 2022 (the “Effective Date”), upon the recommendation of its Compensation, Nomination and Corporate Governance Committee, the Board appointed Wendy L. Dixon, Ph.D. to serve on the Board as a Class III director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brad Bolzon resigned as Director at Black Diamond Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 5, 2022, Brad Bolzon, Ph.D. notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Wendy L. Dixon was appointed as Class III Director at Black Diamond Therapeutics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On April 6, 2022 (the “Effective Date”), upon the recommendation of its Compensation, Nomination and Corporate Governance Committee, the Board appointed Wendy L. Dixon, Ph.D. to serve on the Board as a Class III director

View on SEC.gov

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-043424

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.